# Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis

> **NCT01109940** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 39 (actual)

## Conditions studied

- Ankylosing Spondylitis

## Interventions

- **BIOLOGICAL:** AIN457A

## Key facts

- **NCT ID:** NCT01109940
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2021-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01109940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01109940, "Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01109940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*